MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback
Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.
Why it matters
Attributed market update with source link for portfolio context.